PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life

Inclusion Criteria: * Willing and able to provide written informed consent * Age ≥ 18 years and male * Histologically or cytologically confirmed adenocarcinoma of the prostate * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * One of the following: * CT scan showing indeterminate lymph node(s) in the pelvis that could potentially be treated radically with radiotherapy if found to be positive on PSMA PET. * Suspected oligometastatic disease (\< 4 sites of disease) that could potentially be treated with stereotactic/radical doses of radiotherapy. Exclusion Criteria: * Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection * Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg) * Condition or situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study * Not willing to comply with the procedural requirements of this protocol * Subjects who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration.